Notwithstanding promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from managed care entities. These organizations are often erecting barriers to reimbursement, including significant expense restrictions and approval processes that restrict